Exagen (XGN) Projected to Post Earnings on Monday

Exagen (NASDAQ:XGN - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $14.55 million for the quarter.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.20). The company had revenue of $15.50 million during the quarter, compared to analysts' expectations of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same quarter in the prior year, the firm posted ($0.19) EPS. On average, analysts expect Exagen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Exagen Price Performance

XGN stock traded down $0.45 during mid-day trading on Friday, reaching $5.71. 357,579 shares of the company's stock were exchanged, compared to its average volume of 108,589. The company has a market cap of $102.79 million, a price-to-earnings ratio of -6.07 and a beta of 1.50. Exagen has a 12-month low of $1.38 and a 12-month high of $7.20. The stock's 50 day moving average is $4.54 and its 200 day moving average is $4.11. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05.

Analyst Ratings Changes

A number of research firms recently issued reports on XGN. Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price target on shares of Exagen in a research note on Monday, January 13th. BTIG Research reaffirmed a "buy" rating on shares of Exagen in a report on Wednesday. Finally, William Blair reiterated an "outperform" rating on shares of Exagen in a research report on Wednesday, March 12th.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).